RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2017; 117(01): 03-05
DOI: 10.1160/TH16-10-0782
DOI: 10.1160/TH16-10-0782
Invited Editorial Focus
Cirrhosis as a risk factor for venous thrombosis
Authors
Weitere Informationen
Publikationsverlauf
Received:
14. Oktober 2016
Accepted:
14. Oktober 2016
Publikationsdatum:
10. November 2017 (online)
-
References
- 1 Lewis JH, Bontempo FA, Cornell F. et al. Blood use in liver transplantation. Transfusion 1987; 27: 222-225.
- 2 Garcia-Tsao G, Bosch J. Management of varices and variceal haemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-832.
- 3 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156.
- 4 Lisman T, Porte RJ. Rebalanced haemostasis in patients with liver disease: Evidence and clinical consequences. Blood 2010; 116: 878-885.
- 5 Kleinegris MC, Bos MH, Roest M. et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost 2014; 12: 1647-1657.
- 6 Violi F, Ferro D, Basili S. et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. the CALC group. coagulation abnormalities in liver cirrhosis. Hepatology 1993; 17: 78-83.
- 7 Martinez J, Palascak JE, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest 1978; 61: 535-538.
- 8 Raparelli V, Basili S, Carnevale R. et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology 2016 in press
- 9 Davi G, Ferro D, Basili S. et al. Increased thromboxane metabolites excretion in liver cirrhosis. Thromb Haemost 1998; 79: 747-751.
- 10 Gatt A, Riddell A, Calvaruso V. et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 08: 1994-2000.
- 11 Saliola M, Lorenzet R, Ferro D. et al. Enhanced expression of monocyte tissue factor in patients with liver cirrhosis. Gut 1998; 43: 428-432.
- 12 Hugenholtz GC, Mccrae FL, Adelmeijer J. et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost 2016; 14: 1054-1066.
- 13 Northup PG, McMahon MM, Ruhl AP. et al. Co-agulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528.
- 14 Sogaard KK, Horvath-Puho E, Gronbaek H. et al. Risk of venous thromboembolism in patients with liver disease: A nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101.
- 15 Ferro D, Quintarelli C, Lattuada A. et al. High plasma levels of von willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia. Hepatology 1996; 23: 1377-1383.
- 16 Vairappan B. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol 2015; 07: 443-459.
- 17 Ambrosino P, Tarantino L, Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis: A systematic review and meta-analysis. Thromb Haemost 2017; 117: 139-148.
- 18 Ioannidis JP. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q 2016; 94: 485-514.
- 19 Hugenholtz GC, Northup PG, Porte RJ. et al. Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. Blood Rev 2015; 29: 127-136.
- 20 Shatzel J, Dulai PS, Harbin D. et al. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: A single-center retrospective cohort study. J Thromb Haemost 2015; 13: 1245-1253.
- 21 Gomez Cuervo C, Bisbal Pardo O, Perez-Jacoiste Asin MA. Efficacy and safety of the use of heparin as thromboprophylaxis in patients with liver cirrhosis: A systematic review and meta-analysis. Thromb Res 2013; 132: 414-419.
- 22 Moorehead KJ, Jeffres MN, Mueller SW. A retrospective cohort analysis of pharmacologic VTE prophylaxis and padua prediction score in hospitalized patients with chronic liver disease. J Pharm Pract 2016 in press
- 23 Intagliata NM, Henry ZH, Shah N. et al. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34: 26-32.
- 24 Potze W, Arshad F, Adelmeijer J. et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014; 09: e88390.
- 25 Potze W, Arshad F, Adelmeijer J. et al. Routine coagulation assays underestimate levels of anti-thrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol 2013; 163: 666-673.
- 26 Bogari H, Patanwala AE, Cosgrove R, Katz M. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. Thromb Res 2014; 134: 1220-1223.
- 27 Husted S, de Caterina R, Andreotti F. et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111: 781-782.
- 28 Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. J Hepatol 2013; 59: 358-366.
- 29 Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology 2015; 61: 1435-1436.
- 30 Intagliata N, Maitland H, Northup P, Caldwell S. Treating thrombosis in cirrhosis patients with new oral agents: Ready or not?. Hepatology 2015; 61: 738-739.
- 31 De Gottardi A, Trebicka J, Klinger C. et al. Anti-thrombotic treatment with direct-acting oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2016;
- 32 Intagliata NM, Henry ZH, Maitland H. et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 2016; 61: 1721-1727.
- 33 Ferro D, Basili S, Lattuada A. et al. Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: A potential role for endothelial proco-agulant activation. Ital J Gastroenterol Hepatol 1997; 29: 434-440.
- 34 Violi F, Ferro D, Basili S. et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 1997; 77: 44-47.
- 35 Thalheimer U, Triantos CK, Samonakis DN. et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54: 556-563.
- 36 Warnaar N, Lisman T, Porte RJ. The two tales of coagulation in liver transplantation. Curr Opin Organ Transplant 2008; 13: 298-303.